<DOC>
	<DOCNO>NCT02821520</DOCNO>
	<brief_summary>To compare initial versus delay verteporfin photodynamic therapy ( PDT ) combination conbercept patient symptomatic polypoidal choroidal vasculopathy ( PCV ) .</brief_summary>
	<brief_title>Initial Versus Delayed PDT Combination With Conbercept PCV</brief_title>
	<detailed_description>Polypoidal choroidal vasculopathy ( PCV ) characterize polypoidal choroidal vascular dilatation without abnormally branch vascular network ( BVN ) indocyanine green angiography ( ICGA ) . It consider subtype wet age-related macular degeneration ( wAMD ) . PCV prevalent Asian patient white patient ; nearly half Chinese patient diagnose wAMD actually PCV . However , recently , first choice treatment wAMD shift anti-vascular endothelial growth factor ( VEGF ) drug , bevacizumab ( Avastin , Genentech Inc ) , ranibizumab ( Lucentis , Genentech Inc ) aflibercept ( Eylea , Regeneron , Berlin , Germany ) PDT , vision improve effect confirm regardless race disease subtype . Therefore , eye PCV treat initially anti-VEGF drug , however , limited ability resolve polypoidal lesion , PDT work effectively . Combination therapy PDT anti-VEGF drug provide complementary effect treatment , remain unknown whether PDT administer begin treatment follow-up anti-VEGF therapy . The purpose study compare 12-months treatment result initial delayed PDT combine conbercept ( Lumitin , Chengdu Kang Hong Biotech Co. , Ltd. , Sichuan , China ) PCV .</detailed_description>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>1 . Either gender，age ≥ 40 . 2 . BCVA study entry 34 79 letter ( Snellen Equivalent 20/200 20/25 ) . 3 . Naive symptomatic PCV patient . 4 . Presence PCV assess base ICG active polyp without abnormal vascular network . 5 . No refractive medium opacity small pupil narrow influence fundus examination . 6 . Women must use effective contraception , postmenopausal least month prior trial entry , surgically sterile . 7 . Ability provide write informed consent return study visit . 1 . Active inflammation infection study eye . 2 . Uncontrolled intraocular pressure ( ＞25 mmHg ) study eye . 3 . Ocular condition study eye may impact vision confound study outcome ( e.g . vitreomacular traction , epiretinal membrane BCVA impact , ocular inflammation , retinal vascular disease like diabetic retinopathy diabetic macular edema ) . 4 . Presence centro macular scarring atrophy indicate irreversible BCVA loss . 5 . Prior treatment study eye antiVEGF therapy systemic use antiVEGF product within 3 month prior study entry . 6 . Previous vitrectomy , macular laser treatment , PDT , intraocular steroid study eye . 7 . Allergy fluorescein , ICG , iodine , shellfish . 8 . Pregnant breastfeed woman .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Polypoidal Choroidal Vasculopathy</keyword>
	<keyword>Photodynamic Therapy</keyword>
	<keyword>Conbercept</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
	<keyword>vascular endothelial growth factor</keyword>
</DOC>